Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Ironwood Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091987
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Collaborative arrangements revenue | $113,041 | $85,239 | $219,547 | $126,382 |
| Total revenues | 113,041 | 85,239 | 219,547 | 126,382 |
| Costs and expenses: | ||||
| Research and development | 22,421 | 23,373 | 44,361 | 50,805 |
| Selling, general and administrative | 11,313 | 16,795 | 23,346 | 41,055 |
| Restructuring, net | — | (250) | (40) | 18,309 |
| Total costs and expenses | 33,734 | 39,918 | 67,667 | 110,169 |
| Income from operations | 79,307 | 45,321 | 151,880 | 16,213 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ironwood Pharmaceuticals's R&D?
- Ironwood Pharmaceuticals (IRWD) reported R&D of $22.42M in Q2 2026.
- How has Ironwood Pharmaceuticals's R&D changed year-over-year?
- Ironwood Pharmaceuticals's R&D decreased by 4.1% year-over-year, from $23.37M to $22.42M.
- What is the long-term trend for Ironwood Pharmaceuticals's R&D?
- Over 4 years (2021 to 2025), Ironwood Pharmaceuticals's R&D has grown at a 7.8% compound annual growth rate (CAGR), from $70.41M to $95.14M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Ironwood Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude